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ABSTRACT 
 
The formation of structurally similar insoluble fibrillar protein aggregates, called amyloids, is 
known to cause several neuronal and non-neuronal degenerative diseases such as Alzheimer‟s 
disease, Parkinson‟s disease, Huntington‟s disease and Diabetes mellitus type II. In the present 
scenario, there is still an absence of efficient and medically approved therapeutic agent which 
could effectively inhibit the formation of amyloid fibrils. The similarity in structure of the amyloid 
fibrils of different proteins can be exploited to device a common mechanism to inhibit its 
formation. However, in aqueous solution their tendency to aggregate hinders the effective 
conformational studies. Thus in the present study we employ in silico approach to explore the 
inhibition mechanism of amyloidogenesis based on the interaction of an amyloidogenic protein 
with certain small molecules which have been demonstrated to effectively inhibit fibrillar 
assemblies. We have chosen an amyloidogenic protein called Beta-amyloid (1-42) which is found 
to play a crucial role in the onset of Alzheimer‟s disease. The small molecules chosen here are 
mostly polyphenol molecules which have been found to, specifically and efficiently, inhibit 
amyloid fibrillogenesis in vitro and attenuate their associated cytotoxicity. Based on the results 
obtained we attempt to propose a mechanism by which these small molecules inhibit the fibril 
formation which might be relevant in future for de novo synthesis of small molecule inhibitors for 
the treatment of amyloidosis. 
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INTRODUCTION  
 
One of the most important and startling biological phenomena is the folding of a nascent protein 
into its native three-dimensional structure. The understanding of this complex process elucidates 
the way in which the properties of a molecular system are influenced by evolutionary selection for 
advantageous functions. The key factor behind the amazing diversity in the chemical processes of 
living system is the process of protein folding which leads to generation of a number varied and 
highly specific structures that brings closer important functional groups. 
 
Protein folding is not only crucial for the biological activity of the protein itself but also is 
important for a variety of other cellular processes, which include the molecular trafficking to 
specific cellular destinations and cellular growth regulation and differentiation. It is the native 
structure of the protein that enables it survive in the complex biological environment and interact 
with selectively with other bio-molecules in the surrounding. It is therefore obvious that the failure 
of proteins to fold into their native state, or to remain in their native state, can disrupt normal 
biological functions and cause a very wide variety of pathological conditions [1]. In a highly 
crowded environment, intermolecular interactions may overcome intramolecular ones and these 
misfolded proteins may interact with each other to form aggregates. These aggregates are found to 
be amorphous or highly ordered. The highly ordered form is called “amyloid fibril”. Amyloid 
formation varies greatly with environmental conditions like temperature, pH, oxidative stress, 
ionic strength, peptide concentration etc. These highly ordered protein fibrils form aggregates and 
deposition of which leads to several degenerative diseases such as Alzheimer‟s disease, 
Parkinson‟s disease, Type II diabetes and so on. Thus it is necessary to identify compounds that 
can potentially inhibit or prevent aggregation and amyloid formation effectively. The 
understanding of their mechanism of action can serve as a key therapeutic approach towards 
amyloid diseases.  
In the present study, we have employed in silico approach to identify potential binding sites 
of selected amyloid inhibitor compounds towards amyloidogenesis of amyloid beta (A) peptide, a 
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key peptide which is involved in amyloid formation in brain tissues leading to Alzheimer‟s 
disease. We have further tried to elucidate the mechanism of action of these inhibitor compounds 
towards A amyloidogenesis. These studies will throw some  light towards key interactions which 
play a vital role in blocking protein aggregation and preventing amyloid formation and thus can 
provide essential information towards development of effective therapeutics against amyloidosis. 
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LITERATURE REVIEW 
 
Protein Folding and Misfolding in a cell 
The translation of proteins from the respective genes occurs in the Ribosomes. It is after the 
synthesis of the protein that the folding process starts. However, in some cases, folding in vivo may 
be initiated even before the translation process is over, when the nascent polypeptide chain is still 
not yet released from the ribosome. As earlier discussed the protein folding process is very 
sensitive to the cellular environment. Misfolded proteins might have a tendency to interaction with 
other molecules within the crowded environment of a cell [1]. This is because of the fact that core 
regions buried in the native state get exposed to the solvent. Since the living system are the most 
complicated and yet efficient machinery, there ought to be a proof reading mechanism for the 
misfolding of the proteins. This role is played by the molecular chaperones that are present in all 
cells and cellular compartments. They play a crucial role in the folding of the proteins by 
interacting with nascent chains as they are being released from the ribosome, and by guiding future 
stages of the folding. 
 
In eukaryotic systems, many proteins that are synthesized in a cell are released into the 
extracellular environment, while some of them are translocated into the Endoplasmic 
Reticulum(ER), where they fold correctly into their native state before releasing through the Golgi 
apparatus. There are various types of chaperones and folding catalysts present in the ER, which 
facilitate „quality-control‟ check on the proteins before they are exported [2]. The properly folded 
proteins are directed to the Golgi complex and then to the extracellular environment, while, 
misfolded proteins are transported in a different pathway (the unfolded protein response) in which 
they may be correctly folded or degraded in the cytoplasm by proteasomes. 
 
As it is known clearly that most important function such as translocation across 
membranes, immune response, cell cycle regulation etc., are performed by proteins which owe 
their functionality to their native three-dimensional folded structure that facilitates their binding to 
various molecules. Thus, it is imperative that misfolding or unfolding of the proteins must be 
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ensured quality for maintaining normal function of the cell. However, as we know, no system is 
perfect. There might be a slip even in this intricate machinery which may lead to failure of proper 
of folding of proteins and cause several diseases [3,4]. Such diseases can be broadly classified into 
two categories. 
               
 In first category, protein misfolding and degradation by proof reading machinery of the 
cell results in loss of the function of the protein or the protein itself. For example, in cystic fibrosis, 
F508 mutation occurs in Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) 
protein. This causes protein misfolding and subsequently it is degraded by ubiquitin-proteasome 
pathway [5]. The 1-antitrypsin (1-AT) deficiency is also exemplary in the same class [6]. It is 
noteworthy that the epithelial cells of many organs like lungs, liver, digestive tract, etc. comprises 
the CFTR protein which facilitates the transport of chloride ions in epithelial cells to the outside 
layer of mucus. Moreover, 1-antitrypsin produced in the liver, is found to inhibit the action of 
neutrophil elastase enzyme, which can disrupt connective tissue and damage the lungs. 
            
   The second category comprises amyloidongenic diseases, i.e., disease which are caused 
due to aggregation or amyloid formation facilitated by misfolding of the protein [7,8].  The 
Insoluble protein aggregates or amyloids are toxic to the cell and it has been reported that the 
deposition in important organs and tissue is directly influential in the causation of a number of 
disorders, including Alzheimer‟s and Parkinson‟s diseases, the spongiform encephalopathies and 
type II diabetes [9]. In the next section we look at the formation of these species. 
 
Protein aggregation and amyloid formation 
The wide variety of diseases associated with protein misfolding owe their generation  to the 
conversion of soluble functional peptides or proteins into highly organized insoluble fibrillar 
aggregates. These structures are generally described as amyloid fibrils or plaques when they 
accumulate extracellularly, whereas, when fibrils are formed  inside the cell ,the term “intracellular 
inclusions” is commonly used [7].Amyloidosis is caused by the abnormal deposition of amyloid in 
organs  which may be a cause of various neurodegenerative diseases. The amount of deposition of 
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protein aggregates in organs may greatly vary from undetectable miniscule quantities (in 
neurodegenerative diseases), to even kilograms of protein. 
 
Although it is clear that amyloidosis is a result of amyloid deposition in the tissues, but 
there still is a need to determine the specific molecules and precise mechanisms of the 
pathogenesis and the mode of action. One of the many suggested pathways is the disruption of 
tissue architecture which comprises a direct interaction of the insoluble fibrillar deposits with the 
cell membrane. This leads to the creation of pores which result in the permeabilization of the 
membrane and eventually cell death [10]. Other hypotheses emphasize on the toxicity of amyloid 
aggregates. Some studies indicate variation of the intracellular ion content and changes in redox 
status maybe caused by the deposition of toxic aggregates in the cell. This could be stated as a 
consequence which the cell experiences when it is exposed to membrane permeability caused by 
purification [11]. Whereas in some cases, normal organic functions are supposedly disrupted due 
to direct deposition of heavy masses (few Kgs) of fibrils . 
 
It has been found that amyloid fibrils are formed by a wide variety of proteins which 
negates the earlier assumption of involvement of only few specific proteins associated with known 
clinical disorders. In vitro synthesis of amyloid fibrils by using molecules as myoglobin, and also 
by homopolymers such as polythreonine or polylysine provides a compelling evidence for the 
above statement [12]. The charge of the molecule, secondary-structure and number of hydrophobic 
surfaces influence the relative aggregation rates for a wide range of peptides and proteins [13]. The 
proper folding of a globular protein ensures the burial of the hydrophobic side chains and the main 
polypeptide chain into a core region .Denaturing  conditions like low pH, high temperature etc.,  
cause the unfolding of these proteins and leads to the exposure of the hydrophobic core to the 
solvent. These unfolded or misfolded proteins may be degraded  by proteolysis or  will interact to 
form amyloid fibrils .A nascent polypeptide chain, after its release from the ribosome,  may either 
fold into its native 3D structure,(by sequentially folding into different Intermediates), or it may 
misfold and face consequences such as degradation or aggregation. An amyloid fibril has a unique 
well-ordered misfolded structure. X-ray diffraction studies of other in vitro assemblies indicate the 
presence of natively folded molecules akin to proteins, in oligomers that are functional, macro-
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molecular complexes and naturally occurring protein fibres. The relative thermodynamic and 
kinetic stability governs the interconversion of the various states under any given conditions. In 
living systems, however, the cellular environment, molecular chaperones and proteolytic enzymes 
play a key role in influencing the transitions between the different states. It is, thus, evident that 
failure of these regulatory mechanisms may cause misfolding diseases [14]. 
 
Research work over many years has identified different proteins which cause formation of 
amyloid fibrils in the tissues which leads rise to several diseases in human. A list of some of the 
amyloidogenic proteins and the diseases caused by them is presented in Table1 [15] below: 
 
Disease Protein featured 
Official 
abbreviation 
Alzheimer's disease Beta amyloid Aβ 
Diabetes mellitus type 2 IAPP (Amylin) AIAPP 
Parkinson's disease Alpha-synuclein none 
Transmissible spongiform encephalopathy  PrP APrP 
Huntington's Disease Huntingtin none 
Medullary carcinoma of the thyroid Calcitonin ACal 
Cardiac arrhythmias, Isolated atrial amyloidosis Atrial natriuretic factor AANF 
Atherosclerosis Apolipoprotein AI AApoA1 
Rheumatoid arthritis Serum amyloid A AA 
Prolactinomas Prolactin APro 
Cerebral amyloid angiopathy Beta amyloid Aβ 
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The structurally similar amyloids are formed by a structurally diverse group of proteins. This 
observation gives rise to the speculation that can there be a common mode of therapy against all 
amyloid diseases? 
 
Amyloid biophysics 
Amyloid exhibits a cross-beta sheet quaternary structure. A developed amyloid fibril comprises 2-
5 protofibrils which form helical rope like structure by twisting around each other. The diameter of 
this structure varies from 7-30 nm. The core of amyloid protofilament constitutes the cross  sheet 
structure. Cross sheet interaction stabilizes each protofilament (comprising beta-strands) which 
are perpendicular to the fibrillar axis [15]. The “gold standard‟‟ test which determines the presence 
of the amyloid fibrils is the change in fluorescence intensity of specific dyes such as Thioflavin T 
(ThT) and Congo red (CR) .These dyes  intercalate into the cross beta sheet structure of the fibril 
and thus allow them to be used as analytical tools for detection of fibrils. The breadth of the 
amyloid fibril is traversed by short beta-sheet „‟stacks‟‟ while the length comprises aligned strands. 
The atomistic details of amyloid core have been revealed by recent X-ray diffraction studies 
performed on microcrystals. The "cross-beta" structure was thus experimentally validated with the 
above results which depicted short amyloidogenic regions running perpendicular to the filament 
axis [16]. 
 
A amyloidogenesis 
Alzheimer's disease, also known as Alzheimer disease (AD) in medical literature is the most 
common form of dementia. An uncurable disease, it is characterized by progressive neuro-
dengeneration which eventually leads to death. German psychiatrist and neuropathologistAlois 
Alzheimer decribed it first in 1906 and the disease was thus was named after him. 
 
In Alzheimer‟s disease, the degeneration and death of the brain cells occur that process, 
store and retrieve information [17]. Scientific research has revealed some of the brain changes that 
take place in AD. Abnormal structures called beta amyloid plaques and neurofibrillary tangles are 
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classic biological hallmarks of the disease. Plaques form when specific proteins in the neuron‟s 
cell membrane are processed differently. Normally a transmembrane protein called Amyloid 
precursor protein(APP) is cleaved by an enzyme called α secretase and releases a fragment. 
Another enzyme γ secretase then snips another part of the APP and releases the fragment. These 
fragments are thought to benefit the neurons. In AD, the first cut is made by β secretase, that 
combined with the cut by γ secretase results in the release of short sticky fragments (30-40 amino 
acids) of APP called Beta-amyloid. These fragments clump together and become toxic and 
interfere with the function of neurons. As more fragments are added, these oligomers in increase in 
size and become insoluble resulting in the formation of beta-amyloid plaques. This causes 
disruption of cell-to-cell communication, activation of immune cells that induce inflammation and 
scavenging disabled cells, and, ultimately, killing cells [18]. 
 
Figure 1: Mechanism of formation of amyloid beta peptide from amyloid precurcor protein. 
(Source:http://en.wikipedia.org/) 
 
Beta-amyloid has generally two common isoforms: Aβ40 and Aβ4. Aβ40 is generated by 
cleavage that occurs in the endoplasmic reticulum, while cleavage in the trans-Golgi network 
generates Aβ42. It has been found that of the two, Aβ42 is the more fibrillogenici.e more likely to 
cause amyloid fibril formation, and induce disease states. Mutations in APP induces the increase in 
the relative production of Aβ42 and it has been associated with early onset Alzheimer‟s. Thus 
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scientists proposed a mechanism of Alzheimer's therapy involving modulation of the activity of β 
and γ secretases for the production of mainly Aβ40. 
 
Figure 2: 3D structure of A (1-42) fibrils obtained using Pymol 
 
Therapeutic approach 
Many therapeutic approaches targeting the reduction of amyloid fibrillogenesis include: inhibition 
of secretase activity for decreasing the production of Aamyloid, increasing amyloid degradation 
using amyloid vaccines, or preventing amyloid aggregation employing Antibodies, small peptides, 
or small organic molecules that may inhibit aggregation by specifically binding to the protein. 
Further, few small polyphenolic compounds have been reported to exhibit inhibitory effects in 
vitro and attenuation in associated toxicity of the amyloid fibrils. The early findings on the 
inhibitory effect of polyphenols on amyloid formation came from specific interactions of small 
polyphenolic compounds like Congo Red (CR) and Thioflavin T (ThT), with amyloids and inhibit 
its formation to some extent [19]. Later on several other aromatic phenolic compounds were found 
to exhibit inhibtory effect on amyloid formation in vitro, such as reveratrol, curcumin, rosmarinic 
acid, catechin, tannic acid and so on. These compounds were found to exhibit structural similarities 
like presence of atleast two phenolic rings and more than one –OH groups on the aromatic rings, 
suggesting some common mode of interaction with amyloid fibrils. This indicates involvement of 
some hydrophobic or ring stacking interaction of these phenolic compounds with characteristic 
cross- sheet conformation present in amyloid preventing their further elongation. Also, few 
polyphenolic compounds have exhibited protective effects against amyloid toxicity towards cell 
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culture and primary culture systems, which was mainly attributed to the anti-oxidative properties 
of the polyphenols [20]. 
 
In vitro inhibition of amyloid formation has also been exhibited by few Quinone 
derivatives. Alpha-tocopherolquinone was found to inhibit amyloid beta (A) fibril formation in a 
dose dependent manner and alleviate its toxicity in neuroblastoma cell lines. Further, 
pyrroloquinoline showed significant inhibitory effect on A (1-42) fibrillogenesis and mouse prion 
protein. Several small molecules derived from Quinone were also found to be inhibit 
amyloidogenesis, for e.g., 1,8-dihydroxyanthraquinone was found to  reduce fibril formation and 
neurotoxicity of -amyloid proteins [21]. A flavonoid bicalein is found to facilitate inhibition of 
fibrillation of alpha-synuclein and cause disaggregation of existing fibrils [22]. Catechol 
derivatives such as catecholamines like dopamines and L-dopa exhibited inhibitory effect on 
fibrillogenesis of A and -synuclein [23,24]. Further, rifampicin and its derivatives demonstrated 
the effect of inhibiting toxicity of aggregates of human islet amyloid polypeptide, amylin on PC 12 
cells. This was facilitated by blocking the binding sites on the cell surface which prevented the 
adhesion of the amylin fibrils with the cell surface [25]. For the current study eight small 
molecules were selected, based on literature review, which have demonstrated significant 
inhibitory effects on A42 amyloidogenesis in vitro, but their mechanism of action is still 
unknown. These compounds are as follows:- 
 
Curcumin: It was proposed that the reason for specific binding to the amyloid beta-peptide and 
facilitating the inhibition of fibril formation was the symmetric and compact structure of 
curcumin.[26] Its structural similarity to a beta-sheet breaker, N,N‟-bis(3-
hydroxyphenyl)pyridazine-3,6-diamine, named RS-0406 could be one of the reasons for its 
inhibition characteristics. The important structural feature of the molecule is the two aromatic end 
groups and any alterations in these groups was found to affect its activity. Curcumin, like 
chrysamine G, being lipophilic, is able to cross the blood brain barrier which facilitates its binding 
to plaques Its specific binding to the beta-sheet structures of the plaques formed by aggregation of 
various different proteins indicate that its binding is not dependent on amino acid sequence of the 
proteins but rather its conformation-dependent. 
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Resveratrol:According to certain studies, resveratrol has been found to exhibit property of free 
radical scavenging in a number of cellular types [27]. Free radical scavengers reduce the oxidative 
stress in cell environment which helps in correct folding of the proteins. It was suggested that 
resveratrol acts not only by its anti-oxidant ability, but also by facilitating the inhibition of Aβ 
fibril formation by forming hydrophobic interactions with specific residues in the polypeptide. 
 
Benzofuran derivatives: A number of benzofuran derivatives had been identified which prevent 
the fibril formation in β-amyloid peptide. The inhibition mechanism comprises their binding to 
specific sites on the protein as determined by various assay techniques [28]. The basic 
ethanolamine side chain in these compounds which might be attached to the 2
nd
 or 3
rd
 position in 
the benzofuran ring are supposedly involved in the inhibitory action. This was deduced on the 
basis that derivative compounds lacking this moiety were found to lack the inhibitory action. 
 
Hydroxyindole Derivatives: In a study, 29 indole derivatives were screened to study their 
inhibitory action towards fibril formation and cytotoxicity for cultured pheochromocytoma cells 
which is a benign tumor of sympathetic nervous system. It was found that of the 29 derivatives 
selected, Indole-3-carbinol, 3-hydroxyindole and 4-hydorxyindole were the most effective. The 
studies revealed that it was the presence of –OH group in specific position in the benzopyrrole ring 
interacts with the protein backbone and the different charge and electron density on the ring 
inhibits the π stacking interactions between the Aβ peptides, thereby blocking the elongation of the 
fibrils [29]. 
 
Myo-inositol: Out of the 8 naturally occurring stereoisomers, 4 are reported to be physiologically 
active. Myo-inositol was found to be the most abundant isomer in the brain and more recently 
experiments have revealed its ability to stabilize and attenuate the neurotoxic effects of Aβ42 by 
forming small stable micelles[30]. 
 
2,4 Dinitrophenol: The destabilization of Transthyretin(TTR) molecules results in amyloid fibril 
formation, which have been observed in familial amyloidotic polyneuropathy and cardiomyopathy 
patients.According to a research 2,4-dinitrophenol was found to exhibit highly stabilizing effect on 
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wild-type TTR. Similar interactions were identified with highly amyloidogenic TTR variants: TTR 
L55P and TTR Y78F. The stabilizing effect of the molecule was attributed to its binding capability 
at two hormone-binding sites of the TTR tetramer. This draws the two tetramer closer to each other 
thereby increasing protein stability[31]. 
 
WORK PLAN AND METHODOLOGY 
 
Work plan 
The current work comprises the following specific objectives: 
 Selection of compounds exhibiting inhibitory effect on A peptide amyloidogenesis invitro 
as well as invivo. 
 Identification of amyloidogenic region(s) in the A peptide using different softwares. 
 Identification of binding sites between the A peptide and the inhibitor compounds through 
molecular docking studies using docking tool. 
 Identification of intermolecular interactions between A peptide molecules through 
molecular docking. 
 Comparison and analysis of the results obtained to identify key interactions between the A 
peptideand the inhibitor molecules, and to proposea possible mechanism of inhibition of 
amyloidogenesis. 
 
Methodology 
Selection of amyloidogenic proteins and inhibitor compounds 
Based on earlier studiesone of the amyloidogenic proteins, beta-amyloid(1-42), was selected. The 
pdb file (pdb id: 1IYT) of the protein was retrieved from Protein Data Bank. Similarly, few small 
polyphenolic compounds, which were found to exhibit amyloid inhibitory effect, were selected and 
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the 3D structure files of those compounds were retrieved from PubChem. The detailed list of the 
molecules is mentioned below in Table 2. 
 
Identification of the amyloidogenic regions in the proteins 
Amyloidogenic region of the protein was predicted using web server FoldAmyloid, which predicts 
the specific sequence(s) on a polypeptide chain which are likely to form aggregates based on the 
physicochemical properties of the amino acid residues [32]. 
 
Identification of potential binding sites between the amyloidogenic proteins and inhibitor 
compounds 
Binding sites of the amyloidogenic proteinswere predicted by performing molecular docking using 
Hex software.Tools like „Chimera‟ and „PyMOL‟ were used to visualize the docking complex and 
to generate the 3D structures of the same. LigandScout software was then used to analyze the 
docking results.It automatically generated the images of protein-ligand interactions, depicting the 
various interactions of the ligand with the specific residues in the  receptor. 
 
Comparison of the results obtained by docking to explore the possibility of promiscuous 
inhibitor 
The results obtained from docking studies were compared and analyzed to explore the possibility 
of finding a mechanism which might be relevant for future de novo inhibitors‟ design. 
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RESULTS AND DISCUSSION 
Amyloid beta peptide (1-42) is a key protein involved in the onset of Alzheimer‟s disease. Despite 
extensive research on Aβ amyloidogenesis, currently no specific treatment is available against 
amyloidosis involving clinically approved drugs that inhibit the formation or development of 
existing amyloid deposit. In the current study we had attempted to understand potential binding 
sites between known amyloid inhibitor molecules with Aβ peptide and also to unravel the 
mechanism of inhibition of amyloidogenesis, through insilico approach. 
The 3D structure of the Aβ peptide was retrieved from protein data bank. Aβ is a short 
peptide with 42 residues. It comprises two alpha helical regions that constitutes of residues 8-25 
and 28-38 which are joined by a regular type I beta turn [33]. Further, the analysis of various 
proteins which were found to form amyloid fibrils revealed that there were small stretches of 
sequences in the proteins (amyloidogenic regions) that were mainly responsible for the amyloid 
formation [34]. Based on this and other studies a FoldAmyloid server was developed for prediction 
of amyloidogenic regions in a protein or peptide [35]. This tool to detect amyloidogenic portions in 
a protein had been tested on 144 amyloidogenic and 263 non-amyloidogenic peptides with good 
accuracy. FoldAmyloid web server was used to predict potential regions involved in amyloid 
formation of Aβ peptide. Two amino acid stretches from 16-21 (KLVFFA) and 32-36 (IGLMV) 
were found to be amyloidgenic as shown in Fig. 3. 
 
Figure 3: Solution structure of the amyloid beta-peptide 1-42 (PDB ID- 1IYT).The amyloidogenicresidues as 
predicted by the FoldAmyloid server (amino acid stretches 16-21 and 32-36) are highlighted in red color.  
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Around eight small molecule inhibitor compounds were selected based on their reported inhibitory 
effect on A amyloidogenesis either invitro or invivo. These compounds are- 2,4dinitrophenol, 3-
dihydroxyindole, 4-dihroxyindole, benzofuran, indole-3-carbinol, resveratrol, myoinositol and 
curcumin. All the compounds are aromatic containing one or more benzene rings. The 3D 
structures of eight inhibitor molecules generated using Chimera software are shown in Fig. 4. 
 
 
Figure 4: The 3D structures of the inhibitor molecules retrieved from PubChem and figures generated using Chimera. 
Following are the PubChem ID of the molecules:-a) 2,4 Dinitrophenol (CID 1493) (b)3-hydroxyindole 
(CID 50591)  (c)Benzofuran derivative (CID 3259)d) 4-hydroxyindole (CID 75421)  (e) Indole-3-carbinol 
(CID 3712)  (f) Resveratrol (CID 445154)  (g)Myo-inositol (CID 892)  (h) Curcumin (CID 969516) 
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To identify the binding sites between A peptide and the compounds molecular docking 
was done using Hex software. Figure 5(a) shows the docking result between A peptide and 
2,4dinitrophenol. The ligand binds in the vicinity of the amyloidogenic stretch KLVFFA formed 
by 16-21 residues. Further,Ligand Scout software was used to identify the specific interaction 
between A peptide and 2,4 dinitrophenol, which showed specific hydrogen bonding interaction 
between the nitro group of the ligand and the side chain of lysine residue at position 16 of the 
Apeptide. This shows that the ligand directly interacts with the 16-21 amyloidogenic stretch and 
prevents aggregetaion by masking the amyloidogenic region. 
 
Figure 5: (a) Docking complex of A peptide with 2,4dinitrophenol generated using Hex software (b) corresponding 
Ligand Scout image of the complex showing interactions with specific residues. Amyloidogenic regions in 
A peptide as predicted by FoldAmyloid server are marked in red and the ligand is shown in white. 
 
 
 
Figure 6(a) shows the docking result between A peptide and 3-hydroxyindole. Here the 
ligand was found to interact with the 32-36 amyloidogenic region composed of IGLMV. Ligand 
scout shows hydrophobic interaction between the Leu34 residue of Aand the indole ring of 3-
hydroxyindole. Further, the blue circle over indole indicates interaction between the electron cloud 
of the indole ring and Met35 residue. 
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Figure 6: (a) Docking complex of A peptide with 3-hydroxyindole generated using Hex software (b) corresponding 
Ligand Scout image of the complex showing interactions with specific residues. Amyloidogenic regions in 
A peptide as predicted by FoldAmyloid server are marked in red and the ligand is shown in white. 
 
 
Figure 7(a) shows the docking result between A peptide and 4-hydroxyindole. Here also 
the molecule was found to bind in the vicinity of the amyloidogenic 16-21 stretch and exhibited 
hydrogen bonding interaction between the hydroxyl group of the ligand and the Gln15 residue. 
Further, it also showed interaction between the electron cloud of the indole group and Glu11 
residue. 
 
Figure 7: (a) Docking complex of A peptide with 4-hydroxyindole generated using Hex software (b) corresponding 
Ligand Scout image of the complex showing interactions with specific residues. Amyloidogenic regions in 
A peptide as predicted by FoldAmyloid server are marked in red and the ligand is shown in white. 
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Figure 8(a) shows the docking result between A peptide and a benzofuran derivative. The 
molecule was found to interact with both the amyloidogenic stretches of A peptide. It formed 
specific hydrogen bonding interaction between its phenolic group and Met35 residue present in 
IGLMV amyloidogenic stretch. Further it formed hydrophobic interactions with the neighbouring 
hydrophobic amino acid residues as shown in Fig. 8(b). 
 
 
Figure 8: (a) Docking complex of A peptide with benzofuran generated using Hex software (b) corresponding 
Ligand Scout image of the complex showing interactions with specific residues. Amyloidogenic regions in 
A peptide as predicted by FoldAmyloid server are marked in red and the ligand is shown in white. 
 
  
Figure 9(a) shows the docking result between A peptide and a curcumin. Curcumin also 
exhibited simultaneous interactions with both the amyloidogenic stretches of A peptide. Ligand 
scout shows hydrophobic interactions of curcumin with five hydrophobic amino acid residues of 
A peptide such as Met35, Val39, Phe20, Ile31 and Val24. 
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Figure 9: (a) Docking complex of A peptide with curcumin generated using Hex software (b) corresponding Ligand 
Scout image of the complex showing interactions with specific residues. Amyloidogenic regions in A 
peptide as predicted by FoldAmyloid server are marked in red and the ligand is shown in white. 
 
Figure 10(a) shows the docking result between A peptide and indole-3-carbinol. Unlike 
other inhibitor molecules, this compound exbihited binding near the N terminal domain of the 
peptide far from either of the amyloidogenic stretches. Ligand scout showed  hydrogen bonding 
interaction between the ligand and Phe4 residue. Further, electrostatic interaction was also found 
between the electron cloud of the benzene group of the ligand and the Arg5 residue of A 
 
Figure 10: (a) Docking complex of A peptide with indole-3-carbinol generated using Hex software (b) corresponding 
Ligand Scout image of the complex showing interactions with specific residues. Amyloidogenic regions in 
A peptide as predicted by FoldAmyloid server are marked in red and the ligand is shown in white. 
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Figure 11(a) shows the docking result between A peptide and myoinositol. Myoinositol 
was found to bind with the 16-21 amyloidogenic stretch of A peptide and exhibited specific 
hydrogen bonding interaction with Leu17 residue of the peptide as depicted by Ligand scout. 
 
 
Figure 11: (a) Docking complex of A peptide with myoinositol generated using Hex software (b) corresponding 
Ligand Scout image of the complex showing interactions with specific residues. Amyloidogenic regions in 
A peptide as predicted by FoldAmyloid server are marked in red and the ligand is shown in white. 
 
 
Figure 12(a) shows the docking result between A peptide and resveratrol. This compound 
was found to bind near the 32-36 amyloidogenic stretch of the peptide and formed specific 
hydrogen bonding interaction with Met35 residue and hydrophobic interaction with Val39 residue 
as shown in Figure 12(b). 
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Figure 12: (a) Docking complex of A peptide with resveratrol generated using Hex software (b) corresponding 
Ligand Scout image of the complex showing interactions with specific residues. Amyloidogenic regions in 
A peptide as predicted by FoldAmyloid server are marked in red and the ligand is shown in white. 
 
Thus the docking results showed that except indole-3-carbinol all the seven inhibitor 
molecules bound within or in the vicinity of the amyloidogenic stretches of A peptide as 
predicted by FoldAmyloid software. This finding suggests a possible amyloid inhibitory 
mechanism of these compounds by binding and masking the amyloidogenic region(s) in the 
peptide and preventing self aggregation of the peptide molecules leading to amyloid formation. In 
case of indole-3-carbinol, it is reported to inhibit Afibrillogenesis at a much higher concentration 
compared to other inhibitor molecules, suggesting it may form some micellar structure which is 
necessary for amyloid inhibition [36]. Further, Ligand Scout analysis showed the key role of 
hydrogen bonding and hydrophobic interactions between the peptide and the inhibitor molecules. 
Table 2 shows the list of the eight inhibitor molecules with the free energies of docking with A 
peptide arranged in decreasing order. It can be seen that curcumin exhibited the highest free energy 
of binding suggesting formation of a highly stable complex with A peptide. This result also 
correlates with the reported invivo data showing curcumin as one of the most effective inhibitors 
of amyloid plaque in the Alzheimer‟s disease mice models [37]. 
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Table 2: List of the selected inhibitor molecules with their free energies of docking with A 
Sl.No         Ligand  Name PubChem ID Molecular        
Formula 
Molecular 
Weight(gm) 
      2D Structure Energy(kJ
/mole) 
 
  1 
 
Curcumin 
 
CID 969516 
 
C21H20O6 
 
368.3799 
 
 
- 284.32 
 
 2 
 
Benzofuran derivatives 
 
CID 3259 
 
C20H8I4O5 
 
835.8924 
 
 
 
-278.05 
 
3 
 
Resveratrol 
 
CID 445154 
 
C14H12O3 
 
228.24328 
 
 
 
 -207.12 
 
4 
 
2,4 Dinitrophenol 
 
CID 1493 
 
C6H4N2O5 
 
184.10636 
 
 
 
 
 -171.36 
 
5 
 
Indole-3-carbinol 
 
CID 3712 
 
C9H9NO 
 
147.17386 
 
 
 
 -157.31 
 
6 
 
Myo-Inositol   
 
CID 892 
 
C6H12O6  
 
180.15588 
 
 
 
 -147.79 
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7 
 
 
4-hydroxyindole 
 
CID 75421 
 
C8H7NO 
 
133.14728 
 
 
 
-143.36 
 
8 
 
3-hydroxyindole 
 
CID 50591 
 
C8H7NO 
 
133.14728 
 
 
 
 
 
 -139.98 
 
To further gain insight into the mechanism of fibrillogenesis, docking study was done 
between two A peptide molecules to identify the binding sites and type of intermolecular 
interactions. Figure 11 shows the docking result between two A molecules. The results shows 
strong binding between the two peptide molecules with a binding energy of -640 kJ/mol. Also the 
amyloidogenic regions were found to be aligned close to each other, suggesting that the binding is 
mediated through the amyloidogenic stretches 16-21 and 32-36 of A peptides. This observation 
further validates the amyloid inhibitory effect of the compounds by blocking the amyloidogenic 
regions which are involved in self assembly of the peptide. 
 
                                 Figure 13: Docking complex between two A (1-42) monomers.  
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CONCLUSION 
The current study shows the potential binding sites of known amyloid inhibitor molecules on 
amyloid beta peptide, which is responsible for the onset of Alzheimer‟s disease. Eight inhibitor 
molecules were selected which showed significant inhibition towards A amyloidogenesis in vitro 
but whose mechanism of action was unknown. The amino acid sequences in A peptide, which are 
most prone to aggregation leading to amyloid formation, are predicted based on their 
hydrophobicities and secondary structure propensity, using a webserver named FoldAmyloid. 
Through molecular docking, most of these inhibitor molecules were found to bind within and in 
the vicinity of the predicted amyloidogenic regions of A peptide thereby suggesting their mode of 
action by masking the amyloidogenic regions and preventing further self aggregation of the 
peptide. Further, Ligand Scout analysis showed the essential role of hydrogen bonding and 
hydrophobic interactions in stabilizing the peptide-inhibitor complex which might prevent further 
elongation of the fibrils.  
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